Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by Actuarialon Mar 03, 2017 1:35pm

135 Views

Post# 25928221

RE:RE:RE:RE:RE:Interesting analysis...thoughts?

It is so interesting since I made kind of similar projection of $1.50 per share back to my post on Dec 21, 2016. There is a utility theory saying most people are risk averse, which means people feel much worse losing $1 than gaining $1 in utility measure. And therefore, though the expected value of COT is $1.50, people would like to pay only $0.50 at the moment (please refer to jensen inequality). An opposite example (still risk averse) is that people would like to pay higher premium than expected loss for insurance. It is kind of funny since people who invested in COT actually pursuing huge risk. Anyway, if you are a risk indifference person, buying COT at $.50 per share is a real bargin:)

Bullboard Posts

Changing Europe’s dependency on HREE from China